When is crossover desirable in cancer drug trials and when is it problematic? - Wikidata - thesis-toulmin - TriplyDB

When is crossover desirable in cancer drug trials and when is it problematic?

When is crossover desirable in cancer drug trials and when is it problematic?

http://www.wikidata.org/entity/Q55002458

about

When is crossover desirable in cancer drug trials and when is it problematic?

http://www.wikidata.org/entity/Q55002458

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

When is crossover desirable in cancer drug trials and when is it problematic?

@en

When is crossover desirable in cancer drug trials and when is it problematic?

@nl

type

label

When is crossover desirable in cancer drug trials and when is it problematic?

@en

When is crossover desirable in cancer drug trials and when is it problematic?

@nl

prefLabel

When is crossover desirable in cancer drug trials and when is it problematic?

@en

When is crossover desirable in cancer drug trials and when is it problematic?

@nl

P1433

Q55002458-8E4A67E2-2703-4425-80F3-8309D2970FEF

P1476

Q55002458-DB9EF50F-8BAC-4A4C-A121-543DAB95CEF5

P2093

Q55002458-5C34FCC9-A448-411E-A131-DF6E7CCE636C

Q55002458-B05EDF88-38B1-48D6-BCF5-309184D90DFA

P2860

Q55002458-11EA413E-88AB-401F-8793-40023AAC008A

Q55002458-483A5131-DAE7-4D7A-ADE1-305C6324A6CC

Q55002458-52929555-8420-43E4-AB15-FCF90777C7E2

Q55002458-674D0AAA-B6AC-4A4C-AB8D-2043265017A7

Q55002458-BD02AC73-D0EE-4DB2-A2BA-DFB8CA122CCF

Q55002458-CB668FDA-B133-4552-B7F9-970DD860D8DE

Q55002458-D333CAF3-77B7-4BD0-83ED-7FF23D75EE40

Q55002458-DCF23B26-044E-422E-BFE4-E72348935275

Q55002458-DEA909D0-0334-4C7D-8A80-BB79340A427B

Q55002458-E499752B-F07A-40F3-AE31-8700F8815EC5

P304

Q55002458-F38C723B-F75C-474B-ACE8-D8C2AF6C09B5

P31

Q55002458-18000e0f-0bad-48af-9536-c91a1d40c814

Q55002458-DA6E1AA9-3D52-454F-BFBD-61EAFF890A0E

P356

Q55002458-FFCFA76D-AE8C-4B55-BA09-02476E40ECD2

P433

Q55002458-21DC9119-F383-4249-AEE4-AC9988B9027B

P478

Q55002458-39F50DDB-4B1F-4093-A592-F2EA68A32D65

P577

Q55002458-83B857F3-3629-42C5-937E-230C6E4DC124

P698

Q55002458-4D019144-32A8-43A5-B352-2E2494B9EE0B

P932

Q55002458-F416C329-32F8-43AC-8A1B-38150410F67E

P356

P1433

Annals of Oncology

P1476

When is crossover desirable in cancer drug trials and when is it problematic?

@en

P2093

A Haslam

http://www.w3.org/2001/XMLSchema#string

V Prasad

http://www.w3.org/2001/XMLSchema#string

P2860

Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

The misguided ethics of crossover trials.

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.

Double-crossed: why crossover in clinical trials may be distorting medical science.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

TREATMENT SWITCHING IN CANCER TRIALS: ISSUES AND PROPOSALS.

P304

1079-1081

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDY116

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29648572

http://www.w3.org/2001/XMLSchema#string

P932

5961160

http://www.w3.org/2001/XMLSchema#string